Insider Selling: Monte Rosa Therapeutics (NASDAQ:GLUE) Insider Sells $642,600.00 in Stock

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) insider Filip Janku sold 30,000 shares of the firm’s stock in a transaction that occurred on Wednesday, June 24th. The stock was sold at an average price of $21.42, for a total transaction of $642,600.00. Following the completion of the sale, the insider directly owned 59,992 shares in the company, valued at $1,285,028.64. This represents a 33.34% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Filip Janku also recently made the following trade(s):

• On Tuesday, June 23rd, Filip Janku sold 11,845 shares of Monte Rosa Therapeutics stock. The stock was sold at an average price of $20.22, for a total value of $239,505.90.

Monte Rosa Therapeutics Stock Up 3.9%

Shares of NASDAQ GLUE traded up $0.81 during midday trading on Thursday, hitting $21.66. The stock had a trading volume of 1,768,259 shares, compared to its average volume of 1,328,242. Monte Rosa Therapeutics, Inc. has a 1-year low of $4.12 and a 1-year high of $25.77. The company has a market capitalization of $1.83 billion, a price-to-earnings ratio of -14.64 and a beta of 1.60. The company has a fifty day moving average price of $18.79 and a 200 day moving average price of $18.58.

Monte Rosa Therapeutics (NASDAQ:GLUE) last posted its earnings results on Thursday, May 7th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.06). Monte Rosa Therapeutics had a negative return on equity of 40.99% and a negative net margin of 302.69%.The business had revenue of $4.21 million for the quarter, compared to analyst estimates of $10.95 million. On average, research analysts forecast that Monte Rosa Therapeutics, Inc. will post -1.23 EPS for the current year.

Institutional Investors Weigh In On Monte Rosa Therapeutics

Large investors have recently made changes to their positions in the company. GAMMA Investing LLC acquired a new position in Monte Rosa Therapeutics during the fourth quarter valued at $30,000. Russell Investments Group Ltd. bought a new stake in Monte Rosa Therapeutics in the third quarter worth $32,000. Lazard Asset Management LLC boosted its stake in shares of Monte Rosa Therapeutics by 42.9% during the 2nd quarter. Lazard Asset Management LLC now owns 10,857 shares of the company’s stock worth $48,000 after acquiring an additional 3,262 shares in the last quarter. Nisa Investment Advisors LLC grew its holdings in Monte Rosa Therapeutics by 16.7% during the fourth quarter. Nisa Investment Advisors LLC now owns 3,151 shares of the company’s stock valued at $49,000 after purchasing an additional 451 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. grew its stake in Monte Rosa Therapeutics by 32.5% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,164 shares of the company’s stock valued at $50,000 after buying an additional 776 shares during the last quarter. Institutional investors and hedge funds own 79.96% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on GLUE. Weiss Ratings raised shares of Monte Rosa Therapeutics from a “sell (d-)” rating to a “sell (d)” rating in a research report on Monday, May 11th. JPMorgan Chase & Co. boosted their price objective on Monte Rosa Therapeutics from $30.00 to $31.00 and gave the company an “overweight” rating in a research report on Monday, May 11th. Wells Fargo & Company dropped their price target on shares of Monte Rosa Therapeutics from $30.00 to $29.00 and set an “overweight” rating on the stock in a research note on Wednesday, March 18th. Wall Street Zen cut shares of Monte Rosa Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. Finally, Guggenheim lowered their price objective on shares of Monte Rosa Therapeutics from $34.00 to $30.00 and set a “buy” rating on the stock in a research note on Wednesday, March 18th. Seven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Monte Rosa Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $32.50.

Monte Rosa Therapeutics Company Profile

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.